Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora is asking shareholders to vote at its virtual 2026 annual meeting on March 5, 2026 to elect 11 directors, approve fiscal 2025 executive pay on an advisory basis, and ratify Ernst & Young LLP as auditor for fiscal 2026. The company reports fiscal 2025 revenue of $321.3 billion and total shareholder return of 40%, and says it returned nearly $900 million through dividends and share repurchases.
Cencora highlights progress on its pharmaceutical‑centric strategy, including acquiring Retina Consultants of America and announcing plans to invest $1.0 billion through 2030 to strengthen its U.S. distribution network. Board refresh and governance are central themes: 10 of 11 nominees are independent, eight have joined in the past five years, and D. Mark Durcan became independent Board Chair on October 1, 2025.
The proxy emphasizes board diversity, succession planning, and extensive shareholder engagement on topics such as the CEO transition to Robert P. Mauch, risk oversight, compensation design, and corporate responsibility. It also details committee structures overseeing capital allocation, executive pay, compliance, risk management, and controlled substances distribution.
Cencora, Inc. reported that its Board of Directors appointed Ellen G. Cooper as a director, effective January 20, 2026. To accommodate this change, the Board increased its size from ten to eleven members under the company’s Amended and Restated Bylaws.
Ms. Cooper will receive the same compensation and benefits as other non-employee directors under Cencora’s Compensation Policy for Non-Employee Directors, with all cash and equity amounts pro-rated from her appointment date through the company’s 2026 Annual Meeting of Stockholders. The company states there are no arrangements or understandings with other persons regarding her appointment, no family relationships with existing directors or executive officers, and no related-party transactions requiring disclosure. She has not yet been named to any Board committees.
Cencora also issued a news release on January 22, 2026 announcing the appointment, which is furnished as Exhibit 99.1 to this report.
Form 144 reports a planned insider sale of 5,096 common shares through Fidelity Brokerage Services LLC on the NYSE around 01/20/2026. The planned sale has an aggregate market value of 1,807,704.08 based on the filer’s calculation, compared with 193,993,444 common shares outstanding. The shares to be sold come from 1,333 shares acquired via restricted stock vesting on 11/09/2024 as compensation and 3,763 shares acquired on 01/20/2026 from options originally granted on 11/13/2019 and paid for in cash.
Over the prior three months, Robert Mauch has sold common shares of the same issuer in three transactions: 5,097 shares on 10/20/2025 for gross proceeds of 1,665,699.60, 5,096 shares on 11/18/2025 for 1,868,397.44, and 5,096 shares on 12/18/2025 for 1,750,221.20. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Cencora, Inc. has expanded its financing capacity to support its planned acquisition of OneOncology. The company increased total commitments under its revolving credit facility by $1.0 billion to $5.5 billion, providing additional flexible liquidity.
Cencora also entered into a new senior unsecured term loan agreement totaling $1.5 billion, split into a $500 million tranche maturing two years after draw and a $1.0 billion tranche maturing three years after draw. In addition, the company arranged a separate $3.0 billion 364-day senior unsecured term loan. Proceeds from these loans will help fund the OneOncology purchase price, repay OneOncology’s existing debt, and cover related fees and expenses. Both facilities include leverage covenants generally capped at 4.00 to 1.00, which may temporarily increase to 4.50 to 1.00 when closing a material acquisition, and their funding is conditioned on consummation of the acquisition. These new facilities fully replace previously obtained $4.5 billion bridge financing commitments.
Cencora, Inc. Executive Vice President Silvana Battaglia reported acquiring company shares through an employee stock purchase program. On December 31, 2025, she acquired 27.344 shares of Cencora common stock at a price of $287.088 per share under the Employee Stock Purchase Plan, which is noted as exempt under Rule 16b-3(c) and Rule 16b-3(d). After this purchase, she beneficially owned 18,823.808 shares of common stock in direct ownership.
Cencora, Inc. Executive Vice President Elizabeth S. Campbell reported a small purchase of company common stock. On December 31, 2025, she acquired 33.526 shares of Cencora common stock at a price of $287.088 per share. The filing states this purchase was made through the company’s Employee Stock Purchase Plan under exemptions provided by Rule 16b-3(c) and Rule 16b-3(d). After this transaction, Campbell beneficially owned a total of 23,924.667 shares of Cencora common stock, held in direct ownership.
Cencora, Inc. reported an insider stock sale by an executive vice president on a Form 4. On 12/19/2025, the officer sold 1,677 shares of Cencora common stock at a price of $345 per share, coded as a sale transaction. After this trade, the reporting person beneficially owned 18,796.464 shares of common stock directly. The filing reflects a single non-derivative transaction, with no derivative securities reported.
Cencora, Inc. reported that one of its executive vice presidents, an officer of the company, sold shares of its common stock. On 12/19/2025, the officer disposed of 3,351 shares of Cencora common stock in an open market sale at a price of $342.1 per share. After this transaction, the officer directly beneficially owned 23,891.141 shares of Cencora common stock. This filing reflects a routine insider transaction reported on a Form 4 by a single reporting person.
Cencora, Inc. reported an insider stock transaction by President & CEO and director Robert P. Mauch. On 12/18/2025, he exercised a non-qualified stock option to acquire 3,763 shares of common stock at an exercise price of $86.09 per share, increasing his directly held common stock before the sale to 73,155 shares. On the same date, he reported a sale of 5,096 shares of common stock at a reported price of $343.45 per share. After these transactions, he directly beneficially owned 68,059 shares of Cencora common stock and 7,525 non-qualified stock options. The option exercised was originally scheduled to vest in four equal installments on 11/13/2020, 11/13/2021, 11/13/2022 and 11/13/2023.